{
    "clinical_study": {
        "@rank": "23585", 
        "brief_summary": {
            "textblock": "To determine the safety and tolerance of various combinations of zidovudine (AZT) and\n      didanosine (ddI) administered concurrently. To determine the pharmacokinetics of concurrent\n      AZT and ddI administered orally.  To evaluate the antiviral, immunologic and virologic\n      effects of AZT and ddI administered concurrently."
        }, 
        "brief_title": "A Phase I Study to Evaluate the Pharmacokinetics, Safety and Antiviral Effects of Concurrent Administration of Zidovudine (AZT) and 2'3'-Dideoxyinosine (ddI) in Patients With Human Immunodeficiency Virus (HIV)", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "Acquired Immunodeficiency Syndrome", 
                "HIV Infections", 
                "Immunologic Deficiency Syndromes"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Acyclovir not to exceed two 14-day courses of therapy during trial.  Discontinue ddI\n             while receiving acyclovir.\n\n        Patients must have the following:\n\n          -  Positive HIV antibody using federally licensed ELISA test kit.\n\n          -  CD4 counts < 400 on two consecutive visits within one month prior to entry.\n\n        Prior Medication:\n\n        Allowed:\n\n          -  Zidovudine (AZT) if treated for less than 120 days.\n\n          -  Pharmacologic doses of steroids if given for management of Pneumocystis carinii\n             pneumonia (PCP) (not to exceed 21 days).\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following conditions or symptoms are excluded:\n\n        - Visceral or progressive Kaposi's sarcoma (KS) (defined by > 10 new lesions in the thirty\n        days prior to entry) or patients who require chemotherapy or radiation therapy for\n        Kaposi's sarcoma. Other concurrent neoplasms other than basal cell carcinoma of skin or in\n        situ carcinoma of the cervix. Malabsorption as defined by persistent diarrhea ( > 4\n        stools/day for four weeks) which is unresponsive to antidiarrheal agents. Opportunistic\n        infection requiring maintenance therapy. History of Central Nervous System opportunistic\n        infections (e.g., toxoplasmosis, cryptococcosis). History of seizure disorders. Prior\n        history of pancreatitis. History of peripheral neuropathy or any significant signs or\n        symptoms of neurological disease.  Examinations for peripheral neuropathy should assess\n        changes in extremities. Clinically significant hyperuricemia (tophaceous gout, urate\n        nephropathy). History of cardiomyopathy.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Intravenous pentamidine.\n\n          -  Intravenous trimethoprim / sulfamethoxazole.\n\n          -  Alcohol.\n\n          -  Suppressive acyclovir therapy (see Inclusion Medications).\n\n          -  Allopurinol.\n\n          -  Probenecid.\n\n          -  Isoniazid (INH).\n\n          -  Dipyridamole.\n\n        Concurrent Treatment:\n\n        Excluded:\n\n          -  Radiation therapy for Kaposi's sarcoma.\n\n        Patients with the following are excluded:\n\n          -  Zidovudine (AZT) intolerance as evidenced by inability to tolerate at least 600 mg\n             AZT daily.\n\n          -  Previously intolerant to didanosine (ddI) evidenced by peripheral neuropathy or\n             seizures or pancreatitis or gastrointestinal toxicity or hematologic toxicity.\n\n          -  Diseases or conditions listed under Patient Exclusion Co-existing Conditions.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Zidovudine (AZT) for > 120 days.\n\n          -  Dideoxycytidine (ddC).\n\n          -  Excluded within 30 days of study entry:\n\n          -  Antiretroviral therapy.\n\n          -  Immunomodulators.\n\n          -  Biological response modifiers.\n\n          -  Cytotoxic chemotherapy for Kaposi's sarcoma.\n\n          -  Excluded within 60 days of study entry:\n\n          -  Ribavirin.\n\n        Prior Treatment:\n\n        Excluded within 2 weeks of study entry:\n\n          -  Transfusions.\n\n          -  Excluded within 30 days of study entry:\n\n          -  Radiation therapy for Kaposi's sarcoma.\n\n        Active substance abuse that would impair compliance with study procedures."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002014", 
            "org_study_id": "052A", 
            "secondary_id": "01"
        }, 
        "intervention": [
            {
                "intervention_name": "Zidovudine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Didanosine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antiviral Agents", 
                "Didanosine", 
                "Zidovudine"
            ]
        }, 
        "keyword": [
            "Didanosine", 
            "Drug Evaluation", 
            "Zidovudine"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "941102859"
                    }, 
                    "name": "San Francisco AIDS Clinic / San Francisco Gen Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "331361013"
                    }, 
                    "name": "Univ of Miami School of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02111"
                    }, 
                    "name": "New England Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "981224304"
                    }, 
                    "name": "Univ of Washington"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase I Study to Evaluate the Pharmacokinetics, Safety and Antiviral Effects of Concurrent Administration of Zidovudine (AZT) and 2'3'-Dideoxyinosine (ddI) in Patients With Human Immunodeficiency Virus (HIV)", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002014"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Glaxo Wellcome", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 1991"
    }, 
    "geocoordinates": {
        "New England Med Ctr": "42.358 -71.06", 
        "San Francisco AIDS Clinic / San Francisco Gen Hosp": "37.775 -122.419", 
        "Univ of Miami School of Medicine": "25.789 -80.226", 
        "Univ of Washington": "47.606 -122.332"
    }
}